West Pharmaceutical
WST
#839
Rank
HK$184.58 B
Marketcap
HK$2,549
Share price
0.03%
Change (1 day)
-3.47%
Change (1 year)
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company produces rubber components for packaging injectable drugs and for providing a sterile environment.

P/E ratio for West Pharmaceutical (WST)

P/E ratio as of November 2024 (TTM): 43.7

According to West Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 43.6578. At the end of 2022 the company had a P/E ratio of 29.9.

P/E ratio history for West Pharmaceutical from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202229.9-43.12%
202152.6-12.96%
202060.431.4%
201946.031.31%
201835.0-27.26%
201748.111.21%
201643.3-4.41%
201545.352.23%
201429.7-2.09%
201330.431.5%
201223.136.36%
201116.9-19.4%
201021.017.97%
200917.825.02%
200814.3-24.15%
200718.8-23.7%
200624.645.63%
200516.9-22.97%
200422.093.01%
200311.4-39.39%
200218.8-126.11%
2001-71.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
41.9-3.94%๐Ÿ‡บ๐Ÿ‡ธ USA
16.4-62.34%๐Ÿ‡บ๐Ÿ‡ธ USA
-87.8-301.01%๐Ÿ‡บ๐Ÿ‡ธ USA
56.6 29.72%๐Ÿ‡บ๐Ÿ‡ธ USA
6.59-84.90%๐Ÿ‡บ๐Ÿ‡ธ USA
22.9-47.46%๐Ÿ‡บ๐Ÿ‡ธ USA
32.6-25.36%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
10.9-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.